FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Investing.com - Goldman Sachs maintained its Sell rating and $15.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD) following the company’s inaugural R&D day.
The research firm noted Acadia showcased a broad pipeline focused on neurological and rare indications, framing a risk-unadjusted peak sales potential of $12 billion, or approximately $2.5 billion risk-adjusted. This exceeds the $1.5 billion to $2 billion anticipated peak sales from Nuplazid and Daybue. The company’s current revenue growth of 22.4% and strong financial health score of "GREAT" on InvestingPro suggest solid execution of its commercial strategy.
Goldman Sachs expressed incremental positivity on ACP-204 in Alzheimer’s disease psychosis with Phase 2 readout expected in mid-2026, and Lewy Body dementia psychosis with Phase 2 initiation in the third quarter. Acadia highlighted prior efficacy signals with Nuplazid in both indications and potential for higher dosing with ACP-204 to drive superior efficacy, noting an overall U.S. patient population of 3 million across these conditions.
The company also discussed ACP-101 for Prader-Willi Syndrome with Phase 3 data expected in early fourth quarter and potential PDUFA in third quarter 2026, ACP-211 for major depressive disorder with Phase 2 initiation in fourth quarter, ACP-711 for essential tremor, and ACP-271 which is expected to enter clinical trials for tardive dyskinesia and Huntington’s disease by year-end.
Goldman Sachs continues to monitor potential business development, as Acadia management reiterated interest in rare disease beyond neuroscience during the R&D day presentation.
In other recent news, Acadia Pharmaceuticals has reiterated its expectations for revenue from DAYBUE and NUPLAZID to surpass $1 billion this year. The company plans to initiate seven Phase 2 or Phase 3 clinical studies between 2025 and 2026, with five late-stage study readouts anticipated through 2027. RBC Capital has increased its price target for Acadia Pharmaceuticals to $38 from $26, maintaining an Outperform rating and noting the company’s solid commercial-stage status and emerging pipeline. Cantor Fitzgerald also reiterated its Overweight rating with a $28 price target, highlighting growth drivers for the DAYBUE medication, including a 30% expansion of the field force. Citizens JMP continues to rate the stock as Market Outperform with a $37 price target, emphasizing Acadia’s broad pipeline across CNS and rare diseases. The company is looking forward to potential European Medicines Agency approval for trofinetide in early 2026, which could enhance its market presence. Macquarie has initiated coverage on Neuren Pharmaceuticals, noting its partnership with Acadia as a significant advantage for DAYBUE commercialization. This partnership allows Neuren to receive royalties and milestone payments with minimal expenses. These developments underscore Acadia’s ongoing efforts to strengthen its market position and expand its therapeutic offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.